Po Zhao1, Yali Lu1, Lin Liu1. 1. Department of Pathology, Chinese People's Liberation Army (PLA) General Hospital 28 Fuxing Road, Beijing 100853, China.
Abstract
BACKGROUND: Gastric carcinoma is one of the most aggressive malignancies with an extremely poor prognosis. Recent findings suggest decreasing PHLDA1 (pleckstrin-homologylike domain family A, member1) expression plays a significant role in inhibiting cell migration and tumor invasion. The clinicopathological significance of the expression of PHLDA1 in gastric carcinoma remains to be determined. METHODS: PHLDA1 protein was investigated by immunohistochemistry for the expression status in 336 cases of gastric adenocarcinomas and 60 normal mucosa, and then the results were analyzed with the patient's age, sex, tumor site, size and the histological grade, clinical stage as well as overall median survival time. RESULTS: The expression of PHLDA1 protein was obviously decreased in 57.1% of gastric carcinomas. Carcinomas with loss of expression of PHLDA1 were significantly corresponding to with tumor size (P=0.037), grade (P=0.028), depth of invasion (P=0.001), lymph node metastasis (P=0.008) and stage (P=0.001) but not with age (P=0.194), sex (P=0.312), tumor site (P=0.287) and distal metastasis (P=0.331) respectively. Follow-up data showed that there was a significant difference in overall median survival time between the carcinomas with PHLDA1 negative expression (31.0 months) and those with positive expression (54.0 months) (P=0.001). CONCLUSIONS: Our findings suggest that the decreased expression of PHLDA1 may play an important role in tumor progression, and may become a new adjunct biomarker in the prognosis in gastric carcinoma. A potential role for PHLDA1 in the early detection/or therapy of gastric cancer warrants further investigation.
BACKGROUND:Gastric carcinoma is one of the most aggressive malignancies with an extremely poor prognosis. Recent findings suggest decreasing PHLDA1 (pleckstrin-homologylike domain family A, member1) expression plays a significant role in inhibiting cell migration and tumor invasion. The clinicopathological significance of the expression of PHLDA1 in gastric carcinoma remains to be determined. METHODS:PHLDA1 protein was investigated by immunohistochemistry for the expression status in 336 cases of gastric adenocarcinomas and 60 normal mucosa, and then the results were analyzed with the patient's age, sex, tumor site, size and the histological grade, clinical stage as well as overall median survival time. RESULTS: The expression of PHLDA1 protein was obviously decreased in 57.1% of gastric carcinomas. Carcinomas with loss of expression of PHLDA1 were significantly corresponding to with tumor size (P=0.037), grade (P=0.028), depth of invasion (P=0.001), lymph node metastasis (P=0.008) and stage (P=0.001) but not with age (P=0.194), sex (P=0.312), tumor site (P=0.287) and distal metastasis (P=0.331) respectively. Follow-up data showed that there was a significant difference in overall median survival time between the carcinomas with PHLDA1 negative expression (31.0 months) and those with positive expression (54.0 months) (P=0.001). CONCLUSIONS: Our findings suggest that the decreased expression of PHLDA1 may play an important role in tumor progression, and may become a new adjunct biomarker in the prognosis in gastric carcinoma. A potential role for PHLDA1 in the early detection/or therapy of gastric cancer warrants further investigation.
Authors: Gazi S Hossain; Johannes V van Thienen; Geoff H Werstuck; Ji Zhou; Sudesh K Sood; Jeffrey G Dickhout; A B Lawrence de Koning; Damu Tang; Dongcheng Wu; Erling Falk; Ranjana Poddar; Donald W Jacobsen; Kezhong Zhang; Randal J Kaufman; Richard C Austin Journal: J Biol Chem Date: 2003-05-08 Impact factor: 5.157
Authors: Andrea J Cohen; Alina Saiakhova; Olivia Corradin; Jennifer M Luppino; Katreya Lovrenert; Cynthia F Bartels; James J Morrow; Stephen C Mack; Gursimran Dhillon; Lydia Beard; Lois Myeroff; Matthew F Kalady; Joseph Willis; James E Bradner; Ruth A Keri; Nathan A Berger; Shondra M Pruett-Miller; Sanford D Markowitz; Peter C Scacheri Journal: Nat Commun Date: 2017-02-07 Impact factor: 14.919
Authors: Abbie E Fearon; Edward P Carter; Natasha S Clayton; Edmund H Wilkes; Ann-Marie Baker; Ekaterina Kapitonova; Bakhouche A Bakhouche; Yasmine Tanner; Jun Wang; Emanuela Gadaleta; Claude Chelala; Kate M Moore; John F Marshall; Juliette Chupin; Peter Schmid; J Louise Jones; Michelle Lockley; Pedro R Cutillas; Richard P Grose Journal: Cell Rep Date: 2018-02-27 Impact factor: 9.423